Ranolazine improves diastolic function in spontaneously hypertensive rats.
Diastolic dysfunction can lead to heart failure with preserved ejection fraction, for which there is no effective therapeutic. Ranolazine has been reported to reduce diastolic dysfunction, but the specific mechanisms of action are unclear. The effect of ranolazine on diastolic function was examined in spontaneously hypertensive rats (SHRs), where left ventricular relaxation is impaired and stiffness increased. The objective of this study was to determine whether ranolazine improves diastolic function in SHRs and identify the mechanism(s) by which improvement is achieved. Specifically, to test the hypothesis that ranolazine, by inhibiting late sodium current, reduces Ca(2+) overload and promotes ventricular relaxation and reduction in diastolic stiffness, the effects of ranolazine or vehicle on heart function and the response to dobutamine challenge were evaluated in aged male SHRs and Wistar-Kyoto rats by echocardiography and pressure-volume loop analysis. The effects of ranolazine and the more specific sodium channel inhibitor tetrodotoxin were determined on the late sodium current, sarcomere length, and intracellular calcium in isolated cardiomyocytes. Ranolazine reduced the end-diastolic pressure-volume relationship slope and improved diastolic function during dobutamine challenge in the SHR. Ranolazine and tetrodotoxin also enhanced cardiomyocyte relaxation and reduced myoplasmic free Ca(2+) during diastole at high-stimulus rates in the SHR. The density of the late sodium current was elevated in SHRs. In conclusion, ranolazine was effective in reducing diastolic dysfunction in the SHR. Its mechanism of action, at least in part, is consistent with inhibition of the increased late sodium current in the SHR leading to reduced Ca(2+) overload.
Department of Anesthesiology, Pharmacology, and Therapeutics, Life Sciences Institute, University of British Columbia, Vancouver, Canada.
Sarah
S
Williams
Marc
M
Pourrier
Donald
D
McAfee
Shunping
S
Lin
David
D
Fedida
D000083:Acetanilides / Q000494:pharmacology / Q000627:therapeutic use*; D000375:Aging / Q000378:metabolism; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D003971:Diastole / Q000187:drug effects / Q000502:physiology*; D004195:Disease Models, Animal; D004280:Dobutamine / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology*; D066298:In Vitro Techniques; D008297:Male; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D000069458:Ranolazine; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D013779:Tetrodotoxin / Q000494:pharmacology; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000503:physiopathology
D000083:Acetanilides; D004791:Enzyme Inhibitors; D010879:Piperazines; D004280:Dobutamine; D013779:Tetrodotoxin; D000069458:Ranolazine; D002118:Calcium
cardiomyocyte; diastolic dysfunction; heart function; late sodium current; ranolazine